The involvement of Src kinase during carcinoma metastasis has been explored by using the NBT-II rat carcinoma cell line, which can be induced to scatter in vitro through Src activity. Here we show that Src activity was not required for growth of tumors derived from NBT-II cells injected into nude mice. In contrast, the presence of micrometastases was strictly dependent on Src, since the percentage of mice bearing metastases was dramatically reduced by the expression of a dominant-negative mutant of Src (SrcK -) or of Csk, the natural inhibitor of Src. Furthermore, metastatic cells originating from NBT-II cells displayed a Src activity higher than the parental cells, con®rming that Src gives a selective advantage during the metastatic process. Finally, anatomopathological analysis of the primary tumors arising from NBT-II cells expressing Csk or SrcK -constructs revealed a highly dierentiated epithelial phenotype contrasting with the poor dierentiation of tumors derived from parental cells. The dierentiated phenotype correlated with the presence of desmosomes at the cell periphery and the absence of vimentin intermediate ®laments. Altogether, these data demonstrate that Src activity correlates with the loss of epithelial dierentiation concomitantly with the increase of the metastatic potential of carcinoma cells.
Introduction
Carcinomas are the most frequent cancers that lead to death in a high percentage of cases often consequently to metastasis. The cellular mechanisms governing metastasis appear to be complex and remain largely unknown. Candidates for molecules that might orchestrate the process of metastatic spread include the oncogenes that encode protein kinases. Earlier studies have clearly established a role for both receptor (Baserga, 1994; D'Ambrosio et al., 1995) and nonreceptor tyrosine kinases (Egan et al., 1987; Greenberg et al., 1989) in the transformation of normal cells and the progression toward a malignant phenotype. In particular, product of the c-Src proto-oncogene has been implicated in cancer development (Muthuswamy and Muller, 1994; Ottenho-Kal et al., 1992; Termuhlen et al., 1993) . Src belongs to a family of non-receptor tyrosine kinases that comprises nine members, three of which, Src, Fyn and Yes, are expressed in a broad range of tissues. These enzymes have amino-terminal fatty acids which link them to the cytoplasmic face of membranes, they also have one SH3 and one SH2 domains, a catalytic domain and carboxy-terminal regulatory sequences. It has been reported that Src activity is much higher in metastases, as compared to normal tissues . Other studies have also found an increase in kinase activity for other Src family members, such as Yes (Pena et al., 1995) , Fyn (Takayama et al., 1993) and Lck (Mayer and Ballhausen, 1996) . Signi®cantly, v-src, the oncogenic viral counterpart of normal c-src is more potent in generating highly metastatic cells than activated Ras (Tatsuka et al., 1996) . While it is clear that elevated Src kinase activity correlates with the development of primary tumors, the question as to whether Src activity participates in cancer metastasis is still debated. A recent study documented the presence of an activating mutation of Src at codon 531 in 12% of cases of advanced human colon cancers (Irby et al., 1999) and demonstrated that this mutation promoted metastasis. However, this result was not reproduced in another study (Daigo et al., 1999) . Therefore, mutational activation is unlikely to be the major mechanism of Src activation during malignant progression to metastatic tumors.
If Src is indeed involved in cancer metastasis, the mechanisms whereby it exerts its eects remains elusive. Since the role of Src in promoting cell mitogenesis is well documented (Luttrell et al., 1988 , Roche et al., 1995a Twanley-Stein et al., 1993) , Src could participate in the malignant progression of carcinomas by aecting directly tumor growth. However, there is no experimental or clinical evidence arguing that the metastatic potential depends directly on tumor growth. Therefore, Src may promote metastasis by means other than a direct role on cell proliferation. In that respect, Src has a demonstrated role in the regulation of a variety of biological processes that are associated with changes in cell morphology, including malignancy (Parsons and Weber, 1989) , epithelial plasticity (Warren et al., 1988) and modulation of intercellular adhesion (Volberg et al., 1991) . Accordingly, Src has been recently identi®ed as a key player in transdierentiation processes referred to as epithelium-mesenchyme transitions (EMT) (Boyer et al., 1997; Tsukamoto and Nigam, 1999) , which are likely to be critically involved in carcinoma cell dispersion (Birchmeier et al., 1996; Guarino, 1995; Mareel et al., 1993) . Src may be involved in EMT by phosphorylating speci®c substrates which are mainly cytoskeletal-based components, and molecules localized in cell ± cell and cell ± substrate adhesion sites (Clark and Brugge, 1993; Kellie et al., 1991; Okamura and Resh, 1995; Wu et al., 1991) , the tyrosine phosphorylation of which could in turn modify the cellular architecture. During EMT, Src activity may also interfere with other signaling cascades, such as the Ras pathway. For example, activated Src phosphorylates Shc, an early element of the Ras cascade (McGlade et al., 1992; Nagai et al., 1995) . Finally, Src may generate a unique pathway that culminates in the activation of speci®c transcription factors that are required for EMT events. In that respect, it has been shown that Src family tyrosine kinases control the entry into S-phase of ®broblasts by inducing Myc expression independently of Ras activity (Barone and Courtneidge, 1995) . The three proposed roles of Src in EMTs and EMT-related events such as cancer metastasis could also co-exist.
To investigate the role of Src during metastasis of tumor cells, we have undertaken a comparison of the metastatic properties of cell lines diering only in the expression and activity of Src kinase. We have previously characterized a rat bladder carcinoma cell line, NBT-II, that is induced to scatter after stimulation by various growth factors (FGF-1, EGF, TGF-a) (Gavrilovic et al., 1990; ValleÂ s et al., 1990; B Boyer, unpublished data) . In this cell line, the cytoplasmic protein tyrosine kinase Src is a positive regulator of growth-factor induced epithelial cell dispersion (Boyer et al., 1997; Rodier et al., 1995) . Furthermore, NBT-II cells can be injected subcutaneously into nude mice where they form solid tumors (Jouanneau et al., 1994) . The metastatic spread of tumors derived from NBT-II cell line and from stable transfectants displaying various levels of Src activity represents therefore a good model for evaluating the role of Src in metastasis formation.
Results

Src activity does not influence tumor cell growth
To examine whether Src activity aects tumor development, we took advantage of the fact that the NBT-II rat bladder carcinoma cell line can be grafted into nude mice and produces tumors that will eventually metastasize (Jouanneau et al., 1994) . NBT-II cells were stably transfected with plasmids coding for wild type Src (SrcK + ) and a constitutively activated mutant (Y527FSrc) (Rodier et al., 1995) SrcK + was expressed ®ve times over the endogenous level (Rodier et al., 1995) . Y527FSrc clone expressed the same level of the transgene as compared to endogenous Src but Src activity in this clone was *10 times over the endogenous level. NBT-II cells expressing a dominant negative mutant of Src (SrcK -) and NBT-II cells over-expressing Csk, the natural inhibitor of Src (Imamoto and Soriano, 1993) , were also used in this study. The Csk and SrcK -clones expressed three to four times more the transgene than the corresponding endogenous protein. Two dierent clones of Csk-transfected cells and one clone of SrcK + -and SrcK
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-transfected cells were used in this study. As a control, NBT-II cells transfected with the PSG5 plasmid alone were injected into nude mice. A series of 12 mice were injected with each cell line and were examined for tumor appearance and growth once a week. Tumors became palpable 2 to 3 weeks after injection and grew progressively until they reached a volume of 1500 to 2000 mm 3 , 6 to 8 weeks after injection. When tumors reached that size, mice were sacri®ced. As shown in Figure 1 , the variations in the growth rates are not likely to be due to dierences in Src expression or activity since Csk (clone 1), Srck -and mock-transfected tumors had similar growth curves. The same result was obtained with Csk (clone 2) and SrcK + tumors. The dierences in tumor growth may therefore arise from individual variations between the cell lines that are not linked to Src activity. We concluded from these experiments that Src amount and activity do not in¯uence the growth of tumors derived from the NBT-II cell line.
Src activity affects NBT-II tumor cell metastasis
If Src is involved in carcinoma cell metastasis, inhibition of its activity should result in a signi®cant decrease in the metastatic potential of the NBT-II cell line. NBT-II cells do not give rise to visible metastatic foci in mice injected subcutaneously with the cell line but rather produce micrometastases that can be observed as epithelial foci in cultures of dissociated lymph nodes (Jouanneau et al., 1994) . The percentage of mice bearing metastases was therefore estimated by evaluating whether lymph nodes derived from injected mice were able to give rise to cancer cell colonies in culture. The percentage of lymph nodes containing metastatic cells was estimated according to two calculations. In the ®rst type of calculation, the percentage of mice with metastases was estimated when the primary tumor reached a size of 1500 to 2000 mm 3 regardless of the period of time after injection. In the second type of calculation, the percentage of mice with metastases was calculated for tumors of a constant size (1500 to 2000 mm 3 ) and after the same period of time after tumor cell injection into nude mice (8 weeks). In the latter type of calculation, the number of animals that could be taken into account was reduced, as compared to the ®rst method. As shown in Table 1 , the two types of calculation gave similar results, suggesting that dierences in the metastatic potential of the cell lines re¯ected dierences in cell behavior and not dierences in the growth of the primary tumor. NBT-II cells transfected with the PSG5 vector alone produced tumors of a high metastatic potential, as inferred from the high percentage of lymph nodes containing metastatic cells. Due to the high background of metastasis in the NBT-II cell line, over-expression of Src did not increase substantially the percentage of metastatic lymph nodes. In sharp contrast, tumors derived from NBT-II cells expressing a dominant negative interfering mutant of Src or overexpressing Csk gave rise to signi®cantly less metastasebearing mice. Two dierent clones of Csk-overexpressing NBT-II cells exhibited the same low metastatic potential, suggesting that it did not depend on clonal dierences. The fact that all cell lines exhibited similar attachment rates on plastic (data not shown) ruled out the possibility that the absence of metastatic foci resulted from a defect of the transfected cells to attach to plastic. Due to the reduced number of mice bearing Csk-or SrcK 7 -derived metastases, it was not possible to get valuable data on the number of metastatic foci obtained in each case. Nevertheless, our results suggest that Src activity is a crucial component of the metastatic potential of NBT-II cells.
Metastatic cells originating from cells with low Src activity are not identical to parental NBT-II cells
Metastatic cells were isolated from lymph nodes of mice bearing Csk-over-expressing or SrcK
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-expressing NBT-II tumors. We ®rst observed that the metastatic cells were not able to grow in the presence of geneticin, the antibiotic that was used for selecting the stably transfected cells. In contrast, metastatic cells originating from PSG5-or SrcK + -transfected NBT-II cells were still able to proliferate in the presence of geneticin. This result suggested that metastases originating from Csk-or SrcK 7 -transfected cells had lost the transgene. This was con®rmed by Western blot analysis showing that the amount of Src ( Figure 2a ) and Csk ( Figure 2b ) returned to near basal levels in the majority of metastases derived from SrcK 7 -expressing or Csk-over-expressing NBT-II cells, respectively. Furthermore, since we had previously demonstrated that SrcK -or Csk transfection results in a marked decrease in Src activity, the latter was tested in metastases originating from Csk cells. In these cells, Src activity was 1.5 higher than in the parental Cskexpressing cells and was comparable to that of NBT-II cells ( Figure 2b ). These data suggested that due to the loss of the transgene, the lack of Src inhibition was associated with the ability of cells to metastasize.
On that basis, one could hypothesize that the levels of Src activity is a crucial determinant in NBT-II cell metastasis. It was therefore interesting to test whether the parental NBT-II cell line and the cell lines derived from NBT-II metastases dier in Src level and activity. For that purpose, Western blot analysis was done using equivalent amounts of proteins extracted from NBT-II cells and from three metastatic cell lines obtained by culturing lymph nodes removed from three mice bearing NBT-II tumors. Immunoblotting with anti-Src and anti-P-tyr antibodies (Figure 3 ) revealed a striking increase in Src levels in NBT-II metastases that was associated with a marked increase in the amount of tyrosine-phosphorylated proteins. A kinase assay using enolase as an exogenous substrate for Src immunoprecipitated from cell lysates showed a parallel increase in Src activity in the cells originating from metastases as compared to the parental NBT-II cells, as inferred from the levels of enolase phosphorylation in the metastatic cell lines that were 1.3 to 1.6 times more than in control cells (Figure 3 , lower panel). These results argued for the fact that tumor cells with the highest metastatic potential are those that have the highest Src level and activity.
Interestingly, Src targets such as cortactin and FAK whose tyrosine phosphorylation has been found to be increased during the process of carcinoma cell scattering (Boyer et al., 1997) were hyperphosphorylated in the cell lines derived from micrometastases as compared to the parental NBT-II cell line (Figure 4) . Correlatively, the association of cortactin with Src was substantially enhanced in the metastatic cells, suggesting that, as reported in other cases, cortactin is a direct substrate of Src. Figure 3 Src activity is increased in metastases derived from NBT-II cells. Equivalent amounts of proteins were extracted from the NBT-II cell line and from three dierent metastatic lines derived from three dierent NBT-II tumors. Proteins extracts were subjected to immunoblotting with anti-Src monoclonal antibody or with anti-phosphotyrosine monoclonal antibody. Note that the increase in Src levels parallels increases in P-tyr levels. Immunoblotting of the same extracts was also performed with anti-b-tubulin antibodies as a loading control. Alternatively, Src was immunoprecipitated from equivalent amounts of protein extracts, immobilized on Protein A-Sepharose beads and used in a kinase assay with enolase as an exogenous substrate. The radioactive band corresponds to 32 P-labeled enolase. MW: molecular weights in kDa are indicated b Micrometastases were scored 8 weeks after injection, when tumor size was 1500 ± 2000 mm
NBT-II
The metastatic spread is associated with a fibroblast-like phenotype
When transfected with wild type or constitutively active Src, the NBT-II cell line lost its epithelial characteristics and acquired an elongated phenotype, resembling that of mesenchymal cells (Figure 5a ± c) . In addition, the transfected cells gained the ability to move actively on plastic substrates (data not shown, see Rodier et al., 1995) . Altogether, these modi®cations are reminiscent of the epithelium-mesenchyme transition that arises during embryonic development (Duband et al., 1995; Hay, 1995; Viebahn, 1995) . In sharp contrast, expression of SrcK -or over-expression of Csk did not change the epithelial phenotype of NBT-II cells in culture, which remained polygonal and did not spread on the substrate (Figure 5d,e) . Moreover, expression of the latter constructs enhanced to some extent the epithelial morphology, as inferred from the noticeable compaction of cell islands. Metastases originating from SrcK 7 -and Csk-transfected cells had a clearly dierent morphology (Figure 5f ± i) . Dispersed, ®broblastic-like cells were consistently observed at the periphery of cell clusters. Cell heterogeneity was reproducibly observed in all lines derived from metastases of SrcK 7 -and Csk-transfected clones, and was never seen in the parental cells. It was therefore unlikely to result from an artifact of cell culture. Addition to the cell cultures of PP1, a pyrazolo pyrimidine-type inhibitor that selectively inhibits Src kinases (Schindler et al., 1999) , resulted in the reversion of the elongated phenotype to an epithelial morphology (data not shown), suggesting that the presence of ®broblastic-like cells was correlated with Src activity. The presence of ®broblastic-like cells in cultures of metastatic cells derived from the parental NBT-II line was also reproducibly observed (data not shown), con®rming the notion that the loss of epithelial dierentiation characterizes metastatic cells.
Tumors derived from Csk-and SrcK 7 -expressing cells exhibit a high degree of differentiation
Since the few metastases arising in mice bearing SrcK -and Csk tumors had lost the dierentiated epithelial phenotype characteristic of the parental cell line, the next question was to explore when the morphological modi®cations occurred. For that purpose, histological sections of tumor fragments were examined (Figure 6 ). At low magni®cation (Figure 6a ± d) , SrcK -and Csk tumors were obviously dierent from Y527FSrc and NBT-II-derived tumors. The latter were not clearly delineated and tumor cells were hardly distinguished from the connective tissue (Figure 6a,b) . In sharp contrast, SrcK -and Csk tumors grew as spheroids displaying clear limits with the surrounding host stroma (Figure 6c,d) . At higher magni®cation, Y257FSrc and NBT-II-derived tumor cells were poorly dierentiated (Figure 6e,f) , while SrcK -and Csk tumor cells grew as characteristic islands of polygonal cells interconnected by numerous interdigitations (Figure  6g ,h). The vast majority (more than 90%) of SrcK -and Csk tumors that were examined microscopically displayed the highly dierentiated phenotype while most of Y527FSrc and NBT-II-derived tumors (more than 90%) were poorly dierentiated. It is interesting to note that in all but one case, Csk and SrcK -tumors that gave rise to metastases had a highly dierentiated phenotype, suggesting that the loss of the transfected construct and the transition to a ®broblastic-like phenotype did not arise early during tumor development. The aspect of Csk and SrcK -tumors was reminiscent of the highly dierentiated epithelial phenotype found in epidermoid carcinomas (KopfMaier and Zimmermann, 1991) . Epidermoid carcinomas are characterized by the presence of numerous desmosomes linking neighbouring cells. To con®rm the epidermoid phenotype of SrcK -and Csk tumors, we performed immuno¯uorescence studies on frozen sections (Figure 7 ). Desmosomes were immunolabeled with a anti-desmoplakin antibody. Moreover, since the expression of vimentin intermediate ®lament is a good marker for a poorly dierentiated, ®broblastic-like type of dierentiation (Kirschmann et al., 1999; MorseGaudio et al., 1998; Putz et al., 1999) , vimentin expression was examined in SrcK -and NBT-II-derived tumors. SrcK -tumors were characterized by a strong immuno¯uorescent labeling with anti-desmoplakin antibody, revealing the presence of numerous desmosomes at the cell surface. Moreover, desmoplakin immunolabeling was found in a regular cortical pattern suggesting that desmosomal belts were highly organized (Figure 7a ). Vimentin staining was negative in these tumors (Figure 7b ). Several SrcK -and Csk tumors were analysed and all gave similar results (data not shown). In contrast, many NBT-II tumor cells displayed a cytoplasmic spotted pattern of desmoplakin immunoreactivity, suggesting that desmosomes were (Figure 7c ). Cells displaying this pattern of desmoplakin immunostaining expressed also vimentin, detected as abundant bundles within the cytoplasm (Figure 7d ). The same pattern of desmoplakin and vimentin immunoreactivities was observed in SrcK + -over-expressing and in Y527FSrc-expressing tumors (data not shown). Altogether, these data indicated that inhibition of Src activity correlated with an enhancement of epithelial dierentiation, while disorganization of desmoplakin immunostaining and vimentin expression were the hallmarks of tumors with a high metastatic potential.
Discussion
In this study, we have focused on the mechanisms whereby Src kinase may participate in tumor progression. We have ®rst demonstrated that Src is not involved in NBT-II carcinoma growth, since varying the levels of expression and activity of Src did not lead to coordinated changes in tumorigenicity. This result argues for the fact that Src does not play a crucial role in carcinoma cell proliferation. Accordingly, we have demonstrated previously that Src over-expression does not lead to an increase in the rate of NBT-II cell division (Rodier et al., 1995) . This result is in agreement with data showing that inhibition of c-Src in a mammary carcinoma cell line has no eect on HGF-induced cell proliferation (Rahima et al., 1998) . In contrast, in the adenocarcinoma cell line HT29, expression of an antisense vector speci®c for c-Src dramatically reduces tumor growth (Staley et al., 1997) . Conversely, over-expression of c-Src in colon carcinoma cells enhances primary tumor growth (Irby et al., 1997) . In a model of ovarian cancer grafted into nude mice, the reduction of tumor development by antisense c-src construct was related to the reduction of microvasculature (Wiener et al., 1999) , suggesting that Src activity may in¯uence carcinoma growth indirectly through its eects on angiogenic development. However, we have not found any evidence of a Srcdependent process of vascular development in tumors derived from NBT-II cells harboring various Src constructs (data not shown). The absence of an evident role of Src in the proliferation of epithelial and carcinoma cells contrasts with the well-known function of Src in ®broblast mitogenesis (Roche et al., 1995a,b) . Accordingly, transfection of normal ®broblasts with a construct coding for an activating mutant of Src leads to increased growth of the derived tumor (Irby et al., 1999) . Our data combined with others suggest that the biological eects of the Src kinase may dier according to the cellular context, and particularly to the type of cell dierentiation. They also indicate that the transforming and growth-promoting eects of Src can be dissociated from its ability to elicit the metastatic phenotype. This is the case of the MET oncogene, in which a single point mutation in an intracellular docking site abolishes the metastatic potential while increasing the transforming ability of the oncogenic receptor (Giordano et al., 1997) .
Our results also show that downregulation of the Src kinase is important for maintenance of the epithelial dierentiation. In that respect, it has already been shown that Src activity decreases as intestinal cells dierentiate, suggesting an inverse correlation between epithelial dierentiation and Src activity (Cartwright et al., 1993) . However, controversial results showed that poorly dierentiated colon cancers display signi®cantly reduced Src activity, as compared to moderately or well dierentiated tumors of the same origin (Weber et al., 1992) . One reason for the apparent discrepancy may lie in the fact that Src activity is not the only variable parameter in the latter studies. The implication of Src in the loss of the epithelial phenotype may correlate with its ability to induce epithelial cell scattering (Boyer et al., 1997; g and h) . In h, an insert showing cells at a higher magni®cation highlights the intercellular digits (arrow). Bar represents 60 mm (a ± d) or 20 mm (e ± h) Rodier et al., 1995) through its established function in the disruption of cell ± cell adhesions (Hamaguchi et al., 1993; Matsuyoshi et al., 1992; Owens et al., 2000) . Accordingly, increased Src activity has been reported by others to occur in a variety of cell lines induced to scatter (Cupriti et al., 2000; Fincham and Frame, 1998; Hall et al., 1996; Slack et al., 2001; Warren et al., 1988) . Loss of epithelial dierentiation and acquisition of a ®broblastic-like phenotype, which is known to be involved in the metastatic spread of carcinoma cells, was also associated with metastatic properties, as inferred from the elongated morphology of metastatic cells derived from NBT-II cells. The conclusion could also be drawn from immuno¯uor-escent labeling of NBT-II tumors endowed with a high metastatic potential, which expressed vimentin intermediate ®laments and displayed a reduced and disorganized desmoplakin immunolabeling. Although still controversial, expression of vimentin in tumors of epithelial origin has often been correlated with metastatic spread (Kirschmann et al., 1999; Sim et al., 1999) . In non tumoral cells, expression of vimentin intermediate ®laments is restricted to mesenchymal cells. Therefore, the expression of vimentin in carcinoma cells may be correlated with the ability of metastatic carcinoma cells to undergo a phenotypic switch, designated EMT, toward a ®broblastic-like type of dierentiation (reviewed in Birchmeier et al., 1996; Guarino, 1995; Mareel et al., 1993) . We can therefore conclude that an increase in Src activity is associated with the loss of epithelial morphology and the acquisition of mesenchymal properties that confer an enhanced metastatic potential.
Src kinase needs its catalytic activity to play its role during NBT-II cell metastasis. This is demonstrated by the fact that the SrcK -mutant, in which the tyrosine kinase activity is abolished whereas the interacting SH2 and SH3 domains are preserved, behaves as a dominant-negative, interfering mutant able to abrogate NBT-II cell metastasis. The molecular targets of Src activity that may be crucial for the metastatic process are still to be identi®ed. However, we have shown here that cortactin and FAK, two proteins found to be highly tyrosine phosphorylated in cells transformed by v-Src (Glenney and Zokas, 1989; Kanner et al., 1990; Schaller et al., 1992) , are hyperphosphorylated in the metastase-derived cell lines, as compared to the parental cell line. Accordingly, a strong correlation has been found between the metastatic phenotype of hamster ®broblasts transformed by Rous sarcoma virus and the tyrosine phosphorylation levels of both FAK and paxillin (Rodina et al., 1999) . Tyrosine phosphorylation of FAK is likely to activate this enzyme, which is known to play a central role in cell motility (Cary et al., 1996; Furuta et al., 1995; Ilic et al., 1995 Ilic et al., , 1996 . Cortactin, another well-known substrate of Src, is also involved in cell motility and invasion in vitro and may contribute to tumor cell metastasis (Patel et al., 1998) . Clearly, other experiments are needed to determine what are the Src eector molecules involved in NBT-II cell metastasis. Since the eects governed by Src in NBT-II cells underscore the importance of this enzyme as a therapeutic target in carcinoma cells, ®nding the speci®c molecular elements downstream of Src in the pathway leading to metastasis is a major challenge in cancer biology.
Materials and methods
Cells
The NBT-II cell line, established from a chemically induced rat squamous bladder carcinoma, was maintained in Dulbecco's modi®ed Eagles medium containing 10% FCS. NBT-II clones transfected with the PSG5 plasmid alone as a control, or PSG5 constructs coding for the wild type form of Src (SrcK + ), or a constitutively active mutant of Src in which the regulatory C-terminal tyrosine has been mutated to phenylalanine (Y527FSrc), or a dominant negative form of Src (SrcK -), or Csk, the tyrosine kinase that negatively regulates Src activity, have been described elsewhere (Rodier et al., 1995) . The transfected clones were routinely cultured in Dulbecco's modi®ed Eagles medium containing 10% FCS and geneticin at 400 mg/ml (G418 sulfate; Gibco BRL, Gaithersburg, MD, USA). Csk, SrcK + and SrcK -clones used in this study expressed three to four times more the transgene than the corresponding endogenous protein. Y527FSrc clone expressed the same level of the transgene as compared to endogenous Src but Src activity in this clone was *10 times over the endogenous level. Two dierent clones of Csk-transfected cells and one clone of SrcK + -and SrcK 7 -transfected cells were used in the study. 
Tumorigenicity in nude mice
Six-week-old female nude mice (nu/nu Swiss strain, IaCredo, Les Arbresles, France) were maintained in the animal facilities of Institut Curie under speci®ed pathogen-free conditions. Their care and housing were in accordance with institutional guidelines as put forth by the French Ethical Committee (MinisteÁ re de l'Agriculture, Paris, France) and under the supervision of authorized investigators. Mice were subcutaneously injected in the¯ank with control PSG5-transfected NBT-II cells, SrcK ± -expressing cells, Csk-overexpressing cells, SrcK + -over-expressing cells or F527YSrc-expressing cells. Each animal received 5610 6 cells suspended in 0.1 ml of phosphate-buered saline. Tumor volumes were scored every week by measuring two perpendicular diameters with a caliper. Tumor volume (V) was calculated as previously described (Poupon et al., 1993) : V=a 2 6b/2 where a is the width of the tumor in millimeters and b is the length of the tumor in millimeters. Tumor volumes were calculated for each group of mice. The statistical signi®cance of the dierences between the tumor volumes reached in each group was calculated using Student's t-test. When tumors reached a volume of 1500 to 2000 mm 3 , mice were euthanasized and tumors were surgically removed. Animals were routinely examined for the presence of metastases in various organs (liver, lungs, lymph nodes).
Detection of micrometastases
Micrometastases are carcinoma cells that have disseminated from the primary tumor but are not detectable by conventional anatomopathological observation. Micrometastases were therefore detected after in vitro culture of lymph nodes or fragments of other organs (spleen, liver, lungs). Brie¯y, a fragment of the organ or the axillary, mesenteric and inguinal lymph nodes was excised, cut into small pieces, trypsinized, and grown in vitro under the same conditions as those used for NBT-II and derivate cells. Microscopic examination of the culture at various times after seeding revealed the presence of epithelial foci, derived from metastatic cells. The presence of metastatic foci in cell culture re¯ects the metastatic potential of the cell population.
Processing for microscopic analysis
After removal, fragments of tumors were frozen in liquid nitrogen and then placed into Tissue-Tek embedding medium (OCT compound; Miles), cryosectioned, and stored at 7808C until processed for immuno¯uorescence staining. Anti-DP monoclonal antibody (given by Pr WW Franke, DKFZ, Heidelberg, Germany) and anti-vimentin monoclonal antibody (Amersham Pharmacia Biotech, Buckinghamshire, UK) were used as primary antibodies, followed by Texas Red-and¯uorescein-conjugated anti-mouse antibody, respectively (Jackson Laboratories, West Grove, PA, USA). Alternatively, parts of the tumors were ®xed in Bouin's solution, embedded in paran, and sectioned for anatomopathological microscopic analysis.
Biochemistry
Immunoblot analysis of Src, Csk, FAK and b-tubulin expression, and of P-tyr protein pattern was done essentially as described previously (Boyer et al., 1997) , using the anti-Src Mab 327 (Oncogene Science), the anti-Csk sc-286 (Santa Cruz Biotechnology), the anti-FAK Mab (Transduction Labs), the anti-b-tubulin Mab TUB2.1 (Sigma) and the 4G10 monoclonal anti-phosphotyrosine antibodies (the generous gift of Dr B Druker, Harvard Medical School, Boston, MA, USA). Immunoprecipitation of Src and cortactin was done as described elsewhere (Boyer et al., 1997) . Immunoprecipitation of FAK was performed according to the procedure described previously (Faraldo et al., 2001) . The activity of Src kinase was assayed as described previously (Rodier et al., 1995) using enolase as an exogenous substrate for Src.
